Tanika Pittman, APRN Coordinator

Jill Burke, NP, and Tanika Pittman, APRN, conclude the discussion with practical clinical pearls for APPs caring for patients with multiple myeloma across frontline and early relapse settings.

Tanika Pittman, APRN, discusses the evolving role of APPs in helping patients with multiple myeloma navigate increasingly complex treatment sequences across frontline and relapse settings.

Jill Burke, NP, and Tanika Pittman, APRN, discuss practical considerations for incorporating teclistamab plus daratumumab into the management of patients with multiple myeloma experiencing early relapse, with particular emphasis on patient preparation, safety infrastructure, and APP-led education.

Tanika Pittman, APRN, discusses the individualized approach to selecting subsequent therapy for patients with multiple myeloma experiencing early relapse.

Jill Burke, NP, and Tanika Pittman, APRN, discuss the operational and patient-related challenges of maintaining long-term therapy for multiple myeloma, with an emphasis on adherence, treatment burden, and preserving quality of life.

Tanika Pittman, APRN, explains how minimal residual disease (MRD) assessment can be used to evaluate treatment response in multiple myeloma, emphasizing the importance of communicating the concept in clear, patient-friendly terms.

Jill Burke, NP, and Tanika Pittman, APRN, discuss incorporating shared decision-making into the long-term management of multiple myeloma, particularly as treatment goals expand beyond disease control to include quality of life and minimizing treatment burden.

Tanika Pittman, APRN, discusses practical strategies for maintaining patients with multiple myeloma on effective long-term therapy through proactive toxicity management, supportive care, and ongoing communication with the multidisciplinary team.

Jill Burke, NP, and Tanika Pittman, APRN, discuss how patients with multiple myeloma should be counseled about treatment duration as frontline therapies produce increasingly deep and sustained responses.

Tanika Pittman, APRN, and Jill Burke, NP, discuss practical considerations surrounding the selection and administration of anti-CD38 antibody-based therapies for patients with multiple myeloma, focusing on how clinical trial evidence translates into real-world treatment delivery.

Jill Burke, NP, and Tanika Pittman, APRN, discuss how findings from the PERSEUS and CEPHEUS studies have informed frontline treatment strategies and patient counseling in multiple myeloma, particularly around depth of response and minimal residual disease (MRD) negativity.

Tanika Pittman, APRN, discusses practical strategies for educating patients and caregivers about quadruplet therapy for multiple myeloma, emphasizing the importance of simplifying complex treatment information without overwhelming patients.

Jill Burke, NP, and Tanika Pittman, APRN, discuss the multidisciplinary assessment of patients with multiple myeloma when determining fitness, transplant eligibility, and suitability for frontline quadruplet therapy.

– Jill Burke, NP, introduces the program and Tanika Pittman, APRN, who brings more than 15 years of oncology experience from the UAMS Myeloma Center.